Synlett 2009(11): 1842-1846  
DOI: 10.1055/s-0029-1217361
LETTER
© Georg Thieme Verlag Stuttgart ˙ New York

Unexpected Formation of Fluorine-Containing Multiply Substituted Dispirocyclohexanes from the Reaction of Ethyl-4,4,4-trifluoro-1,3-dioxobutanoate and 2-Arylideneindane-1,3-diones

Baifan Daia, Liping Song*a,b, Pengyuan Wanga, Hai Yia, Weiguo Caoa, Guifang Jinb, Shizheng Zhu*b, Min Shaoc
a Department of Chemistry, School of Science, Shanghai University, 99 Shangda Road, Shanghai 200444, P. R. of China
Fax: +86(21)66132797; e-Mail: lpsong@shu.edu.cn;
b Key Laboratory of Organofluorine Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 354 Fenglin Lu, Shanghai 200032, P. R. of China
c Instrumental Analysis and Research Center, Shanghai University, Shanghai 200444, P. R. of China
Further Information

Publication History

Received 16 February 2009
Publication Date:
12 June 2009 (online)

Abstract

In the presence of a catalytic amount of piperidine ­(10 mol%), reaction of ethyl 4,4,4-trifluoro-3-oxobutanoate 3 and ­2-arylidene-indane-1,3-diones 4 gave the unexpected fluorine-­containing multiply substituted dispirocyclohexanes 5 in good yields. The structures of compounds 5 were fully confirmed by spectroscopic methods and elemental analysis. A representative compound 5a was further confirmed by XRD analysis. A plausible reaction mechanism for the formation of compounds 5 was presented.

    References and Notes

  • 1a Gross U. Rüdiger S. Organo-Fluorine Compounds, In Methods of Organic Chemistry (Houben-Weyl)   Vol. E10a:  Baasner B. Hagemann H. Tatlow JC. Thieme; Stuttgart: 1999.  p.18-26  
  • 1b Smart BE. J. Fluorine Chem.  2001,  109:  3 
  • 2a Banks RE. Smart BE. Tatlow JC. Organofluorine Chemistry: Principles and Commercial Applications   Plenum Press; New York: 1994. 
  • 2b Hiyama T. Organofluorine Compounds: Chemistry and Properties   Springer; Berlin: 2000. 
  • 3 Burger’s Medicinal Chemistry and Drug Discovery   Vol. 1:  Abraham DJ. John Wiley and Sons; New York: 2003. 
  • 4a Ismail FMD. J. Fluorine Chem.  2002,  118:  27 
  • 4b Organofluorine Compounds in Medicinal Chemistry and Biomedical Applications   Filler R. Kobayashi Y. Yagulpolskii LM. Elsevier; Amsterdam: 1993. 
  • 4c Welch JT. Ewarakrishnan SE. Fluorine in Bioorganic Chemistry   John Wiley; New York: 1991. 
  • 4d Becker A. Inventory of Industrial Fluoro-Biochemicals   Eyrolles; Paris: 1996. 
  • 5a Kozikowski AP. Acc. Chem. Res.  1984,  17:  410 
  • 5b Howe RK. Shelton BR. J. Org. Chem.  1990,  55:  4603 
  • 5c De Amici M. De Michelli C. Sani VM. Tetrahedron  1990,  46:  1975 
  • 5d Caroll WA. Grieco PA. J. Am. Chem. Soc.  1993,  115:  1164 
  • 5e Early WG. Oh T. Overman LE. Tetrahedron Lett.  1988,  29:  3785 
  • 5f Ban Y. Taga N. Oishi T. Chem. Pharm. Bull.  1976,  24:  736 
  • 5g Ban Y. Seto M. Oishi T. Chem. Pharm. Bull.  1975,  23:  2605 
  • 5h Ban Y. Taga N. Oishi T. Tetrahedron Lett.  1974,  15:  187 
  • 5i Van Tamelen EE. Yardley JP. Miyano M. Hinshaw WB. J. Am. Chem. Soc.  1969,  91:  7333 
  • 5j Kobayashi J. Tsuda M. Ageme K. Shigemori H. Ishibashi M. Sasaki T. Mikami Y. Tetrahedron  1991,  47:  6617 
  • 5k James DM. Kunze HB. Faulkner JD.
    J. Nat. Prod.  1991,  54:  1137 
  • 5l Sinclair A. Stockman RA. Nat. Prod. Rep.  2007,  24:  298 
  • 5m Xu S. Arimoto H. Uemura D. Angew. Chem. Int. Ed.  2007,  46:  5746 
  • 5n Clive DLJ. Yu M. Wang J. Yeh VSC. Kang S. Chem. Rev.  2005,  105:  4483 
  • 5o Yashin NV. Averina EB. Grishin YK. Kuznetsova TS. Zefirov NS. Synthesis  2006,  279 
  • 5p Bernard AM. Frongia A. Guillot R. Piras PP. Secci F. Spiga M. Org. Lett.  2007,  9:  541 
  • 5q Salim H. Piva O. Tetrahedron Lett.  2008,  49:  2994 
  • 6a Berger STA. Lemek T. Mayr H. ARKIVOC  2008,  (x):  37 
  • 6b Mosher WA. Brenne JL. J. Org. Chem.  1971,  36:  3383 
  • 6c Zalukaevs LP. Anokhina I. J. Gen. Chem. USSR.  1964,  34:  834 ; Zh. Obshch. Khim. 1964, 34, 840
  • 6d Soliman FM. Said MM. Maigali SS. Heteroat. Chem.  1997,  8:  157 
  • 7a Babu ARS. Raghunathan R. J. Heterocycl. Chem.  2006,  43:  1357 
  • 7b Babu ARS. Raghunathan R. Gayatri G. Sastry GN. J. Heterocycl. Chem.  2006,  43:  1367 
  • 7c Babu ARS. Raghunathan R. Synth. Commun.  2007,  37:  451 
  • 7d Babu ARS. Raghunathan R. Tetrahedron Lett.  2006,  47:  9221 
  • 7e Babu ARS. Raghunathan R. Tetrahedron  2007,  63:  8010 
  • 8a Ramachary DB. Anebouselvy K. Chowdari NS. Barbas CF. J. Org. Chem.  2004,  69:  5838 
  • 8b Ramachary DB. Chowdari NS. Barbas CF. Synlett  2003,  1910 
  • 9 Dhawan SN. Sharma M. Bajaj S. Sharma K. Sharma S. Heterocycles  2007,  71:  1509 
  • 10 Harig M. Kuck D. Eur. J. Org. Chem.  2006,  1647 
  • 11a Zalukaevs LP. Anokhina I. J. Gen. Chem. USSR.  1964,  34:  834 ; Zh. Obshch. Khim. 1964, 34, 840
  • 11b Zimaity T. Afsah ES. Hammouda M. Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem.  1979,  17:  578 
  • 11c Zalukaevs LP. Vnenkovskaya DG. Zh. Org. Khim.  1966,  2:  672 
  • 11d Stankevich EI. Yanags GY. J. Gen. Chem. USSR.  1962,  32:  1123 ; Zh. Obshch. Khim. 1962, 32, 1146
  • 11e Pati HN. Das U. De Clercq E. Balzarini J. Dimmock JR. J. Enzym. Inhib. Med. Chem.  2007,  22:  37 
  • 12a Tu SJ. Jiang B. Zhang JY. Zhang Y. Jia RH. Li CM. Zhou DX. Cao LJ. Shao QQ. Synlett  2007,  480 
  • 12b Pabolkova EA. Trukhin EV. Kasem YA. Berestovitskaya VM. Russ. J. Gen. Chem.  2006,  76:  1349 
  • 12c Kozlov NG. Tarasevich VA. Vasilovskii DA. Baselaeva LI. Russ. J. Gen. Chem.  2006,  42:  107 
  • 12d Pizzirani D. Roberti M. Recanatini M. Tetrahedron Lett.  2007,  48:  7120 
  • 12e Chen Y. Tu SJ. Jiang B. Shi T. J. Heterocycl. Chem.  2007,  44:  1201 
  • 12f Shi DQ. Ni SN. Yang F. Shi JW. Duo GL. Li XY. Wang XS. Ji SJ. J. Heterocycl. Chem.  2008,  45:  963 
  • 12g Tu SJ. Jiang B. Zhang JY. Jia RH. Zhang Y. Yao CS. Org. Biomol. Chem.  2006,  4:  3980 
  • 12h Li M. Yang WL. Wen LR. Li FQ. Eur. J. Org. Chem.  2008,  2751 
  • 13a Song SD. Song LP. Dai BF. Yi H. Jin GF. Zhu SZ. Shao M. Tetrahedron  2008,  64:  5728 
  • 13b Li XF. Song LP. Xing CH. Zhao JW. Zhu SZ. Tetrahedron  2006,  62:  2255 
  • 13c Li DM. Song LP. Li XF. Xing CH. Peng WM. Zhu SZ. Eur. J. Org. Chem.  2007,  3520 
  • 13d Li DM. Song LP. Song SD. Zhu SZ. J. Fluorine Chem.  2007,  128:  952 
  • 14 Wu DY. Ren ZJ. Cao WG. Tong WQ. Synth. Commun.  2005,  35:  3157 
15

A Typical Experimental Procedure for the Preparation of 5a To a mixture of ethyl 4,4,4-trifluoro-3-oxobutanoate (184.0 mg, 1.0 mmol) and 2-benzylidene-indane-1,3-dione (468.0 mg, 2.0 mmol) in MeCN (3.0 mL) was added a catalytic amount of pipreridine (8.5 mg, 0.1 mmol). The resulting mixture was stirred at r.t. until the reaction was completed
(8 h, monitored by TLC). The solvent was removed under reduced pressure. And then the residue was purified by column chromatography on silica gel using PE-EtOAc [6:1 (v/v)] as eluent to afford 5a as a colorless solid in 78% yield.

16

Spectroscopic Data for Products 5 Compound 5a: colorless solid (509.0 mg), mp 211-214 ˚C. ¹H NMR (500 MHz, CDCl3): δ = 0.89 (t, J = 7.0 Hz, 3 H, OCH2CH 3), 3.84 (qd, J 1 = 7.0 Hz, J 2 = 3.5 Hz, 2 H, OCH 2CH3), 4.51 (d, J = 12.5 Hz, 1 H, CH), 4.56 (s, 1 H, CH), 5.19 (d, J = 12.5 Hz 1 H, CH), 5.65 (s, 1 H, OH), 6.37 (br, 1 H, ArH), 6.59-7.06 (m, 8 H, ArH), 7.32-7.42 (m, 4 H, ArH), 7.54-7.56 (m, 3 H ArH), 7.66-7.69 (m, 1 H, ArH), 7.93-7.95 (m, 1 H, ArH). ¹9F NMR (470 MHz, CDCl3): δ= -71.63 (s, 3 F, CF3). IR (KBr): 3402, 3062, 2981, 2932, 1745, 1711, 1594, 1247, 1184 cm. ESI-MS: m/z = 653 [M + H]+, 670 [M + NH4]+. Anal. Calcd for C38H27F3O7: C, 69.94; H, 4.17. Found: C, 70.06; H, 4.06.
Compound 5b: colorless solid (510.0 mg), mp 227-229 ˚C. ¹H NMR (500 MHz, CDCl3): δ = 0.91 (t, J = 7.0 Hz, 3 H, OCH2CH 3), 1.78 (s, 3 H, ArCH3), 2.04 (s, 3 H, ArCH3), 3.84 (qd, J 1 = 7.0 Hz, J 2 = 3.5 Hz, 2 H, OCH 2CH3), 4.47 (d, J = 12.5 Hz, 1 H, CH), 4.51 (s, 1 H, CH), 5.15 (d, J = 12.5 Hz, 1 H, CH), 5.63 (s, 1 H, OH), 6.15 (br, 1 H, ArH), 6.50-6.70 (m, 4 H, ArH), 6.82-6.86 (m, 2 H, ArH), 7.24-7.36 (m, 2 H, ArH), 7.39-7.43 (m, 2 H, ArH), 7.66-7.69 (m, 4 H, ArH), 7.92-7.93 (m, 1 H, ArH). ¹9F NMR (470 MHz, CDCl3): δ = -71.65 (s, 3 F, CF3). IR (KBr): 3408, 3029, 2986, 1741, 1712, 1247 cm. ESI-MS: m/z = 681 [M + H]+, 698 [M + NH4]+. Anal. Calcd for C40H31F3O7: C, 70.58; H, 4.59. Found: C, 70.33; H, 4.77.
Compound 5c: colorless solid (617.0 mg), mp 246-247 ˚C. ¹H NMR (500 MHz, CDCl3): δ = 0.96 (t, J = 7.0 Hz, 3 H, OCH2CH 3), 3.89 (qd, J 1 = 7.0 Hz, J 2 = 3.5 Hz, 2 H, OCH 2CH3), 4.69 (d, J = 12.5 Hz, 1 H, CH), 4.71 (s, 1 H, CH), 5.20 (d, J = 12.5 Hz, 1 H, CH), 5.45 (s, 1 H, OH), 6.84-7.28 (m, 4 H, ArH), 7.43-7.53 (m, 3 H, ArH), 7.58-7.71 (m, 5 H, ArH), 7.76-7.80 (m, 2 H, ArH), 7.97-8.00 (m, 2 H, ArH). ¹9F NMR (470 MHz, CDCl3): δ = -71.67 (s, 3 F, CF3). IR (KBr): 3420, 3058, 2979, 2934, 1746, 1710, 1595, 1248, 1188 cm. ESI-MS: 743 [M + H]+, 760 [M + NH4]+. HRMS (MALDI/DHB): m/z calcd for [C38H25F3N2O11 + H]+: 743.1483; found: 743.1501; m/z calcd for [C38H25F3N2O11 + Na]+: 765.1303; found:765.1309.
Compound 5d: colorless solid (584.0 mg), mp 243-244 ˚C. ¹H NMR (500 MHz, CDCl3): δ = 0.95 (t, J = 7.0 Hz, 3 H, OCH2CH 3), 3.87 (qd, J 1 = 7.0 Hz, J 2 = 3.5 Hz, 2 H, OCH 2CH3), 4.49 (d, J = 12.5 Hz, 1 H, CH), 4.53 (s, 1 H, CH), 5.11 (d, J = 12.5 Hz, 1 H, CH), 5.52 (s, 1 H, OH), 6.36-7.07 (m, 7 H, ArH), 7.33-7.51 (m, 4 H, ArH), 7.60-7.72 (m, 3 H, ArH), 7.72-7.75 (m, 1 H, ArH), 7.94-7.96 (m, 1 H, ArH). ¹9F NMR (470 MHz, CDCl3): δ = -71.70 (s, 3 F, CF3). IR (KBr): 3408, 3071, 2986, 2937, 1739, 1713, 1593, 1243, 1196 cm. ESI-MS: m/z = 721, 723, 725 [M + H]+, 738, 740, 742 [M + NH4]+. Anal. Calcd for C38H25Cl2F3O7: C, 63.26; H, 3.49. Found: C, 62.87; H, 3.58.
Compound 5e: colorless solid (551.0 mg), mp 222-223 ˚C. ¹H NMR (500 MHz, CDCl3): δ = 0.92 (t, J = 7.0 Hz, 3 H, OCH2CH 3), 3.86 (qd, J 1 = 7.0 Hz, J 2 = 3.5 Hz, 2 H, OCH 2CH3), 4.49 (d, J = 12.5 Hz, 1 H, CH), 4.54 (s, 1 H, CH), 5.11 (d, J = 12.5 Hz, 1 H, CH ), 5.55 (s, 1 H, OH), 6.09 (br, 1 H, ArH) 6.49-6.93 (m, 6 H, ArH), 7.37-7.49 (m, 4 H, ArH), 7.56-7.60 (m, 3 H, ArH), 7.70-7.73 (m, 1 H, ArH), 7.93-7.95 (m, 1 H, ArH). ¹9F NMR (470 MHz, CDCl3): δ = -71.71 (s, 3 F, CF3), -112.61 (m, 1 F, ArF), -114.13 (m, 1 F, ArF). IR (KBr): 3397, 3087, 2983, 2938, 1743, 1711, 1511, 1247, 1190 cm. ESI-MS: m/z = 689 [M + H]+. Anal. Calcd for C38H25F5O7: C, 66.28; H, 3.66. Found: C, 66.04; H, 3.49.

Compound 5f: colorless solid (620.0 mg), mp 241-243 ˚C. ¹H NMR (500 MHz, CDCl3): δ = 0.94 (br, 3 H, OCH2CH 3), 3.87 (br, 2 H, OCH 2CH3), 4.51 (br, 2 H, CH), 5.13 (br, 1 H, CH), 5.58 (s, 1 H, OH), 6.34-7.01 (m, 7 H, ArH), 7.43-8.00 (m, 9 H, ArH). ¹9F NMR (470 MHz, CDCl3): δ = -71.63 (s, 3 F, CF3). IR (KBr): 3440, 3055, 2984, 1744, 1710, 1593, 1249, 1235, 1176 cm. ESI-MS: m/z = 721, 723, 725 [M + H]+, 738, 740, 742 [M + NH4]+. Anal. Calcd for C38H25Cl2F3O7: C, 63.26; H, 3.49. Found: C, 62.91; H, 3.37.
Compound 5g: colorless solid (743 mg), mp 265-266 ˚C. ¹H NMR (500 MHz, CDCl3): δ = 0.95 (br, 3 H, OCH2CH 3), 3.88 (br, 2 H, OCH 2CH3), 4.48 (br, 2 H, CH), 5.13 (br, 1 H, CH), 5.58 (s, 1 H, OH), 6.61-7.13 (m, 7 H, ArH), 7.35-7.76 (m, 8 H, ArH), 7.95-8.02 (m, 1 H, ArH). ¹9F NMR (470 MHz, CDCl3): δ = -71.61 (s, 3 F, CF3). IR (KBr): 3441, 3072, 2983, 1744, 1711, 1592, 1250, 1178 cm. ESI-MS: m/z = 809, 811, 813 [M + H]+, 826, 828, 830 [M + NH4]+. HRMS (MALDI/DHB): m/z calcd for [C38H25Br2F3O7 + Na]+: 830.9811; found: 830.9817.

17

In particular, in the cases of compounds 5f and 5g, the ¹H NMR spectrum showed broad signals due to decreased rotational flexibility of the highly puckered structures.

18

CCDC 720376 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 (1223)336033.